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Clostridium difficile infection (CDI), a leading cause of nosocomial infection, is a serious disease in North America, Europe, and
Asia. CDI varies greatly from asymptomatic carriage to life-threatening diarrhea, toxic megacolon, and toxemia. The incidence
of community-acquired infection has increased due to the emergence of hypervirulent antibiotic-resistant strains. These new
strains contribute to the frequent occurrence of disease relapse, complicating treatment, increasing hospital stays, and increas-
ing morbidity andmortality among patients. Therefore, it is critical to develop new therapeutic approaches that bypass the de-
velopment of antimicrobial resistance and avoid disruption of gut microflora. Here, we describe the construction of a single het-
eromultimeric VHH-based neutralizing agent (VNA) that targets the two primary virulence factors of Clostridium difficile,
toxins A (TcdA) and B (TcdB). Designated VNA2-Tcd, this agent has subnanomolar toxin neutralization potencies for both C.
difficile toxins in cell assays. When given systemically by parenteral administration, VNA2-Tcd protected against CDI in gnoto-
biotic piglets andmice and to a lesser extent in hamsters. Protection from CDI was also observed in gnotobiotic piglets treated
by gene therapy with an adenovirus that promoted the expression of VNA2-Tcd.
Clostridium difficile infection (CDI) is currently one of the lead-ing causes of nosocomial infection (1, 2) and is fast becoming
a cause of community-acquired diarrhea in previously low-risk
populations, including children, healthy adults, and pregnant
women (1–7). Manifestations of CDI vary from asymptomatic
colonization; mild or moderate diarrhea; a severe or fulminant
illness with complications, including pseudomembranous colitis,
toxic megacolon, and small bowel ileus; or even systemic inflam-
matory response syndrome, a multisystem organ failure that can
be fatal (8). The emergence of antibiotic-resistant hypervirulent
strains and the increase in disease relapse have complicated the
treatment of CDI, leading to increases in hospital stay, morbidity,
and mortality (1).
Clostridium difficile is a Gram-positive, spore-forming anaero-
bic bacterium that produces two toxins, designated TcdA and
TcdB (9), which are the major virulence factors of CDI (10). They
are large exotoxins that bind to human colonocytes, causing in-
flammation, fluid accumulation, and mucosal injury manifested
as pseudomembranous colitis (11).
C. difficile survives, persists, and produces the two exotoxins
in the gut after prolonged treatment with broad-spectrum an-
tibiotics reduces normal microflora (12). The extensive use of
antibiotics for treatment of CDI has increased the emergence of
resistant strains, leading to a dramatic increase in the incidence
of disease relapse estimated at 20% to 35% (13). Consequently,
there is an urgent need to develop novel, nonantibiotic thera-
pies that prevent persistence and toxin production by C. difficile
and minimally impact normal gut microflora. Ideally, approaches
that specifically target toxins instead of bacterial cells and elimi-
nate the possibility of antimicrobial resistance are favored (14,
15). Several therapeutic approaches are currently under develop-
ment, including antibiotics (8, 16, 17), probiotics (18–23), fecal
transplants (24–26), toxin-binding resins or polymers (27), vac-
cines (16, 28–30), and toxin-specific antibodies (Abs) (31–38).
Several but not all antitoxin antibodies improve CDI outcomes in
animal models and clinical trials (32, 34, 35, 39–42), but these
conventional antibodies are costly and challenging to engineer.
There is some evidence from the pig model (43) that antibodies
against TcdB alone may be sufficient for treating CDI; however,
there are conflicting data on the roles of the toxins in disease
(44–46).
As an efficient alternative, we produced and tested heavy-
chain-only VH domains (VHHs), generated by Camelidae species,
seeking VHHs that neutralize each of the two C. difficile toxins.
DNAs encoding these unconventional IgGs (IgG2 and IgG3) are
easily cloned (47) and can be expressed at high levels in soluble
form (48). The VHH protein products are generally more stable
than conventional antibodies and frequently bind the active sites
of targeted proteins (48–50). We previously showed that bispecific
VHH-based neutralizing agents (VNAs) are highly efficacious as
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antitoxins in animal models of exposures to botulinum neurotox-
ins (51), ricin (52), Shiga toxins (53), and anthrax (54), signifi-
cantly outperforming their monomer VHH components. To
achieve protection from CDI, a VNA was engineered and ex-
pressed in bacteria containing four VHHs, two (AH3, AA6) that
neutralize TcdA and two copies of the 5D VHH (5D, 5D) that
neutralizes TcdB (41). This VNA, called ABA, provided potent
protection from CDI in a mouse model.
While some reports have indicated that TcdA does not play a
significant role in disease pathogenesis in the gnotobiotic pig
model of CDI (43), other evidence has shown that TcdA and TcdB
toxins contribute to fulminant disease in hamsters (55) and in
some mouse models of CDI (56). Since VHH agents remain func-
tional when linked into multimers, we have chosen to include
VHHs that neutralize both Tcd toxins in our antitoxin agent, as
this should be effective in all of the models of CDI. In the current
study, we chose to reengineer the ABA VNA based on recent re-
sults (57) and unpublished data showing that two different toxin-
neutralizing VHHs against the same target combined into a single
linked construct create a more effective antitoxin in vivo than a
homodimer of only one toxin-neutralizing VHH. In our new
VNA, VNA2-Tcd, we replaced one of the two copies of the 5D
VHH in ABA with a different TcdB-neutralizing VHH, E3. Spe-
cifically, VNA2-Tcd is a tetraspecific agent that contains 5D and
E3 VHHs targeting TcdB linked to the two TcdA-neutralizing
VHHs, AH3 and AA6. In this report, we test the ability of VNA2-
Tcd to protect against CDI pathology in mouse, hamster, and
gnotobiotic piglet models of this disease when administered as a
protein therapeutic or by adenoviral gene therapy.
MATERIALS AND METHODS
Ethics with IACUC statement. Treatment and care of all animals used in
experiments followed institutional animal care and use committee guide-
lines. All animal studies performed were approved by the Tufts University
Institutional Animal Care and Use Committee.
Plasmid construction. Synthetic DNA was prepared in which the cod-
ing DNAs for the two most potent neutralizing VHHs that we reported
previously for TcdA (AH3, AA6) and TcdB (5D, E3) (41) were linked
together, each separated by DNA encoding a flexible spacer (GGGGS)3, to
encode a VHH tetraspecific, heteromultimeric VNA (AH3/5D/E3/AA6)
called VNA2-Tcd. This DNA was inserted into expression vector pET32b
in fusion with Escherichia coli thioredoxin as described by Tremblay et al.
(53) to create the Trx/VNA2-Tcd expression plasmid.
Protein purification. The Trx-VNA2-Tcd-6His/pET32b plasmid was
transformed into Rosetta-gami (DE3) E. coli, and fermentation was as
follows: 20 liters of LB medium with 100 g/ml ampicillin and 34 g/ml
chloramphenicol was incubated at 15°C and expression induced with 1
mM isopropyl--1-thiogalactopyranoside (IPTG) at an optical density at
600 nm (OD600) of 0.6 for 20 h (58). The protein was captured by Ni
affinity chromatography and eluted with a 0.5 M imidazole gradient at pH
7.5. It was further purified by gel filtration chromatography (HiLoad Su-
perdex 200 26/60; GE Life Sciences) with 20 mM HEPES (pH 7.8), 200
mM NaCl, 1 mM dithiothreitol (DTT), and 1 mM EDTA elution buffer.
The protein eluted as a monomer from the gel filtration column. Recom-
binant protein was visualized by SDS-PAGE/Coomassie and by Western
blotting using an anti-E-tag antibody (Bethyl) at a 1:5,000 dilution. In
some experiments, the protein was treated for endotoxin removal using
the Triton X114 phase partitioning method. The final endotoxin concen-
tration in the endotoxin-free preparation was below 0.01 endotoxin units
(EU)/mg as determined by the PyroGene recombinant Factor C assay
(Lonza). Fermentation, purification, dialysis, and endotoxin removal
were performed by ARVYS Proteins Inc. (Trumbull, CT).
Adenovirus vector construction and preparation. The generation of
recombinant replication-incompetent adenovirus type 5 (Ad5)-based
vectors has been previously described (59). Briefly, in a modification from
reference 60, the pShCMV-JGf7 shuttle plasmid was used for subcloning
the VNA2-Tcd coding sequence (54) under the control of the mammalian
cytomegalovirus (CMV) promoter and was followed by the bovine
growth hormone poly(A) signal. A control vector Ad/VNA1-Stx was cre-
ated in a similar manner with the sequence from two VHHs against Shiga
toxins (Stx) (61). This control vector results in the secretion of a Stx-
reactive Ab with no binding to Tcd. Each shuttle plasmid was linearized
and employed for homologous recombination with the pAdEasy-1 plas-
mid carrying the viral genome, resulting in the selection of the plasmid
containing the recombinant Ad5 genome that incorporates either the
VNA2-Tcd or VNA1-Stx expression cassette in place of deleted viral E1
genes. The resultant plasmids were validated by PCR, restriction analyses,
and sequencing to confirm the incorporation of the VNA2-Tcd or VNA1-
Stx expression cassette within the corresponding recombinant viral ge-
nome. The plasmids were linearized with PacI to release the inverted
terminal repeats of the viral genomic DNA and transfected into 293 cells
to rescue replication-incompetent Ad/VNA2-Tcd. The rescued Ad/
VNA2-Tcd and Ad/VNA1-Stx vectors were upscaled, purified by centrif-
ugation on CsCl gradients as previously described (60), and dialyzed
against phosphate-buffered saline (PBS) (8 mM Na2HPO4, 2 mM
KH2PO4 [pH 7.4], 137 mM NaCl, 2.7 mM KCl) containing 10% glycerol
and stored at80°C. The titers of physical viral particles (vp) were deter-
mined by the methods of Maizel et al. (62).
Neutralization assay. Vero cells (ATCC) at a concentration of 2.4
104 cells/100 l of medium (Dulbecco modified Eagle medium [DMEM]
high glucose plus 1 mM sodium pyruvate, 2 mM L-glutamine, 50 U/ml
and 50g/ml penicillin [Pen]/streptomycin [Strep] [pH 7.4] [HyClone])
were plated in 96-well plates overnight for 90% to 95% confluence, prior
to the addition of VNA2-Tcd added in serial dilutions (in medium) from
100 g/ml to 1.0 fg/ml and either 2 ng to 12.5 ng/ml TcdA and 0.25 to 2
ng/ml TcdB or TcdA and TcdB in a 24-h cytotoxicity/cell rounding assay
(41).
Enzyme-linked immunosorbent assay. EIA/RIA 96-well high-bind-
ing plates (Corning Costar) coated with 0.5 to 5 g/ml of recombinant
TcdA (rTcdA) or rTcdB or rTcdA rTcdB overnight at 4°C were used for
binding assays. Plates were washed 3 times with 1 PBS  0.1% Tween
followed by 3 times with 1 PBS and blocking solution (4% to 5% nonfat
dry milk in 1 PBS  0.1% Tween) for 1 h at room temperature (RT)
with rocking. Serially diluted VNA2-Tcd, serum, or fecal samples diluted
in blocking solution were incubated for 1 h at RT with rocking and were
washed as above. Equivalent control samples were spiked with a known
amount of VNA2-Tcd for use as an internal standard. Goat anti-E-tag
horseradish peroxidase (HRP)-conjugated antibody (Bethyl Labs), di-
luted 1:5,000 in blocking solution, was incubated for 1 h at RT with rock-
ing, washed as above before adding 3,3=,5,5=-tetramethylbenzidine
(TMB) microwell peroxidase substrate (KPL) to develop (incubated for
10 to 40 min), stopped with 1 M H2SO4, and read at 450 nm on a ELx808
ultra microplate reader (BioTek Instruments) (51). VNA2-Tcd levels in
unknown samples were determined by comparison of their signals to
those of internal standards as previously described (60, 61, 63–65).
Mouse systemic toxin challenge. Six-week-old C57BL/6 female mice
were intraperitoneally (i.p.) injected with a single dose of VNA2-Tcd (50
g/mouse) 1 h prior to i.p. injection of TcdA (100 ng/mouse), TcdB (200
ng/mouse), or TcdA plus TcdB (100 ng/mouse and 200 ng/mouse, respec-
tively). Mice were monitored for signs and symptoms of toxemia (includ-
ing lethargy, depression, anorexia, dehydration, ruffled coat, and
hunched posture). Moribund mice were euthanized following IACUC-
approved removal criteria.
Mouse CDI challenge. To mimic the human condition and facilitate
colonization with C. difficile, ten 6-week-old C57BL/6 female mice re-
ceived filter-sterilized antibiotics (kanamycin, gentamicin, colistin, met-
ronidazole, and vancomycin) in drinking water for 5 days followed by 2
Therapeutic Treatment for C. difﬁcile Infection
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days of water alone. After 2 days of drinking water, each mouse received
one 100-l i.p. injection of clindamycin (2 mg/ml). One day later, mice
were orally challenged (66) with 106 spores of an NAPI/027/BI C. difficile
strain, which was designated strain UK6 (67) only (control group), or
inoculated with spores and administered VNA2-Tcd (25 to 50g/mouse)
at 4, 24, and 48 h postchallenge (treated group). Blood was collected at 72,
96, and 120 h postchallenge for VNA titers.
Hamster CDI challenge. Again, to mimic the human condition and
facilitate colonization with C. difficile, seventeen 110- to 135-g male
golden Syrian hamsters were administered clindamycin (30 mg/kg of
body weight) via oral gavage for 5 days prior to oral inoculation with 1,000
C. difficile strain UK6 spores. Infected control hamsters were administered
clindamycin inoculated with UK6 spores and given sterile PBS i.p. 2 times
per day for the duration of the experiment. VNA2-Tcd-treated hamsters
were administered clindamycin, inoculated with spores, and given puri-
fied VNA2-Tcd (1 mg/kg) i.p. 2 times a day for the duration of the exper-
iment. A blood sample was collected at time of euthanasia for detection of
VNA2-Tcd in serum. Necropsies were performed on euthanized animals,
and tissues were collected for histopathologic examination.
Pig CDI challenge. Thirty gnotobiotic piglets were derived via Cae-
sarean section and maintained in sterile isolators for the duration of the
experiment (65). Five groups of piglets were orally inoculated with 106 C.
difficile UK6 spores (groups 1 to 5), and group 6 was the uninfected con-
trol group (summarized in Table 1). Group 1 (n 3) received VNA2-Tcd
(1 mg/pig) 4 h prior to oral inoculation with spores, and group 2 (n 3)
received VNA2-Tcd (1 mg/pig) 18 h after oral inoculation with spores.
After the initial dose, the treated groups received 2 doses of VNA2-Tcd (1
mg/pig) per day either i.p. or intramuscularly (i.m.) for the duration of the
experiment (Table 1). The Ad/VNA2-Tcd-treated group (group 3; n 9)
was given 1.0 1011 viral particles intravenously (i.v.) 1 day prior to oral
inoculation with 106 C. difficile UK6 spores and 3 days postinfection (Ta-
ble 1). Group 4 (n 6) received VNA-Tcd buffer as a control 4 h prior to
oral inoculation with 106 C. difficile UK6 spores and at 24 h postinocula-
tion and then every 12 h until the termination of the experiment (Table 1).
Group 5 was given control adenovirus expressing an unrelated VNA (n
6) at 1.0 1011 viral particles i.v. 1 day prior to oral inoculation with 106
C. difficile UK6 spores and 3 days postinfection (Table 1). Group 6 (n 3)
was uninfected (Table 1). From all piglets, fecal samples were collected for
bacterial culture and blood samples were collected 1 to 3 times (when
possible) during the experiment and at the time of euthanasia for VNA
titers. Necropsies were performed on all animals, and tissues were col-
lected for histopathologic examination.
Histology. Tissue samples were collected during necropsy and pre-
served in 10% neutral buffered formalin. Formalin-fixed samples were
embedded in paraffin, sectioned at 5 m, and stained with hematoxylin
and eosin using routine histochemical techniques at Tufts University
Cummings School of Veterinary Medicine (TCSVM) Histopathology Ser-
vice Laboratory (http://vet.tufts.edu/histology-service/). Light micro-
scopic examination and lesion evaluation were performed by a board-
certified veterinary pathologist (G. Beamer) with results reported as
previously described for severity (minimal, mild, moderate, marked),
epithelial ulceration, luminal contents, and quantification (64).
Briefly, a quantitative assessment of colitis severity was performed by
counting neutrophilic foci in colon sections from each sample. Foci
were observed between colonic crypts in the lamina propria in 10
random fields with 20 magnification.
RESULTS
VNA2-Tcd construction, expression, and protein purification.
We previously identified two individual VHHs with strong neu-
tralizing activity against TcdA (AH3, AA6) and two VHHs that
neutralized TcdB (5D, E3). Results with these VHHs, and VHHs
to other toxins (51–53), have shown that covalently linking two
toxin-neutralizing VHHs into bispecific heterodimer VHH-based
neutralizing agents (VNAs) results in substantially enhanced in
vitro and in vivo antitoxin potency compared to equimolar pools
of unlinked VHHs. We thus engineered the recombinant expres-
sion of a tetraspecific VHH heteromultimer containing the four
different VHHs, two each having TcdA- and TcdB-neutralizing
properties, which were all separated by flexible spacer peptides
(Fig. 1). The VNA2-Tcd heterotetramer was purified using Ni
affinity and gel filtration chromatography, treated for endotoxin
removal using a detergent-based method (0.01 EU/mg), and
visualized following SDS-PAGE, revealing a purity of about 71%
for full-length heterotetramers, and the remaining protein bands
were almost entirely represented by trimeric and dimeric trunca-
tions of full-sized VNAs based on Western blotting (see Fig. S1 in
supplemental material). For gene therapy, an adenovirus vector
(Ad5) was engineered to promote the expression and secretion of
VNA2-Tcd (Ad/VNA2-Tcd) following transduction of mamma-
lian cells.
In vitro characterization. The 50% inhibitory concentration
(IC50) of VNA2-Tcd was determined by dilution cytotoxicity as-
say using Vero cells and 100 pM of recombinant TcdA or 0.6 pM of
recombinant TcdB and serially diluted VNA2-Tcd. The estimated
IC50 was about 100 pM for TcdA and about 10 pM for TcdB,
indicating that VNA2-Tcd is capable of neutralizing both toxins
when present at near equimolar doses to the two Tcd toxins in
these assays (Fig. 2A and B).
Mouse systemic toxin challenge. We assessed the potency of
VNA2-Tcd to neutralize toxins A and B in a systemic mouse chal-
lenge using 6-week-old C57BL/6 female mice. Six groups of mice
(5 mice per group) were injected i.p. with TcdA and/or TcdB in
the presence or absence of VNA or VNA alone and were moni-
tored for signs of toxemia. Initial systemic toxin doses of 100 to
200 ng of TcdA and 100 to 800 ng of TcdB were tested individually
to determine the 100% lethal dose (LD100) at 24 h. The LD100
doses for each toxin were then used in the systemic challenge. The
control group mice that were administered 100 ng/mouse of TcdA
and 200 ng/mouse of TcdB (i.p.) were either moribund (eutha-
nized) or died within 4 h postchallenge. Other groups were ad-
ministered the following treatments: (i) no treatment, (ii) VNA2-
Tcd only (no toxin), (iii) VNA2-Tcd TcdA, (iv) VNA2-Tcd
TABLE 1 Pig treatment groups
Group No. of pigs Control buffer (ml) Control adenovirus (vp) VNA2-Tcd (mg) Ad/VNA2-Tcd (vp) Time (h) Route
1 3 NAa NA 1 NA 4, 24, then every 12 i.p.
2 3 NA NA 1 NA 18, then every 12 i.m.
3 9 NA NA NA 1.0 1011 24, 72 i.v.
4 6 1 NA NA NA 4, 24, then every 12 i.m.
5 6 NA 1.0 1011 NA NA 24, 72 i.v.
6 3 NA NA NA NA NA NA
a NA, not applicable.
Schmidt et al.
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TcdB, or (v) VNA2-Tcd  TcdA/TcdB. VNA2-Tcd treatments
were a single i.p. injection of VNA2-Tcd (2.5 mg/kg) 1 h prior to
toxin challenge. No mice in these 5 groups (see Table S1 in the
supplemental material) showed any signs or symptoms of tox-
emia, and all remained healthy until termination of the experi-
ment at 7 days post-toxin challenge.
Mouse CDI challenge. Two groups (5 mice each) of 6-week-
old C57BL/6 female mice were treated for 5 days with an antibiotic
cocktail in drinking water and administered a single i.p. injection
of clindamycin prior to being orally challenged with 106 C. difficile
(UK6 strain) spores. The control group received spores plus PBS,
and the treated group received spores and VNA2-Tcd injected i.p.
at 4, 24, and 48 h postchallenge. The VNA2-Tcd group received an
initial dose of 25g/mouse (1.25 mg/kg) at 4 h postchallenge and
two additional doses of VNA2-Tcd (50 g/mouse [2.5 mg/kg]) at
24 and 48 h postchallenge. The control group (spores  PBS)
experienced weight loss at days 1, 2, and 3 postchallenge, and most
mice began to gain weight on day 3 or 4 postchallenge, while the
VNA2-Tcd-treated group experienced weight loss only on day 1
postchallenge and began to regain weight on day 2 postchallenge
(Fig. 3A). The difference in weight between the control and treated
groups was only statistically significant on day 2 postchallenge.
One hundred percent of the control animals developed diarrhea,
and 60% were moribund or died (Fig. 3B). Only 1 mouse in the
VNA2-Tcd-treated group developed diarrhea, which was resolved
by day 2 postchallenge. All mice in the VNA2-Tcd-treated group
survived for the duration of the experiment (Fig. 3B). Blood was
collected from mice 24, 48, or 72 h after administration of the final
dose of VNA2-Tcd. Serum VNA2-Tcd levels were measured by
enzyme-linked immunosorbent assay (ELISA) and ranged from
1.9 to 6.1 g/ml (see Fig. S2A in the supplemental material). Se-
rum TcdA and TcdB neutralization abilities tested by cytotoxicity/
cell rounding assay were similar for all treated mice with a 1:10
dilution of serum providing about 50% protection from rounding
(see Fig. S2B).
Hamster CDI challenge. Hamsters were reported to be rela-
tively resistant to the UK6 strain of C. difficile (68), so we per-
formed initial experiments and established that treating with 5
days of oral clindamycin followed by 1,000 UK6 spores induced
CDI disease in 100% of Syrian hamsters (not shown). To test
VNA2-Tcd efficacy, two groups of male golden Syrian hamsters
were administered clindamycin (30 mg/kg) orally for 5 days prior
to inoculation with 1,000 UK6 spores. The control group (6 ham-
sters) received spores plus PBS, and the treated group (11 ham-
FIG 1 Synthesis and purification of VNA2-Tcd. (A) Schematic diagram of TcdA and TcdB toxins, respectively. GTD, enzymatic glucosyltransferase domain;
TMD, transmembrane domain; RBD, receptor binding domain. AH3 and AA6 bind in the GTD region and the TMD region of TcdA, respectively, and 5D and
E3 bind to different regions of the GTD in TcdB. (B) Diagram of the heterotetramer VNA2-Tcd, which was synthetically generated and contains two potent
neutralizing VHHs to each toxin. The protein contains a thioredoxin protein at the amino end, followed by four VHHs separated by a flexible spacer peptide with
a carboxyl-terminal E-tag peptide and an albumin-binding peptide to increase serum persistence.
FIG 2 In vitro and in vivo neutralization of toxins. (A and B) In vitro neutral-
ization assay using Vero cells incubated with 100 pM TcdA or 0.6 pM TcdB per
well for 24 h with serial dilutions of VNA2-Tcd as indicated. Percent cell
rounding (cytotoxicity) was assessed after 24 h. The IC50 was determined using
the GraphPad nonlinear fit of log-transformed concentrations. Log IC50 for
TcdA 2.0 and the IC50 was 106.4; Log IC50 for TcdB 1.24 and the IC50 was
13.3.
FIG 3 Protection against CDI in mice using VNA2-Tcd. Mice were treated
with an antibiotic cocktail for 3 days in drinking water and given a single
injection of clindamycin i.p. 1 day prior to infection with 106 PFU of Clostrid-
ium difficile UK6 spores alone or UK6 spores and 3 doses of VNA2-Tcd (2.5
mg/kg at 4, 24, and 48 h) postinfection. (A) Weight of mice in treated (VNA2-
Tcd) and untreated (PBS) groups during the 6-day study. A Mann-Whitney U
test was performed to compare the control and VNA-treated mice per day.
Only day 2 (*) showed statistically significant P values of 0.021 weights be-
tween the control and treated groups. (B) Survival percentage with time for
each group.
Therapeutic Treatment for C. difﬁcile Infection
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sters) received spores and 1 mg/kg of VNA2-Tcd injected i.p. two
times a day for the duration of the experiment. All hamsters in the
control and treated groups except for one treated hamster devel-
oped diarrhea. In the control group, hamsters developed diarrhea
between days 5 through 7, and all were moribund and euthanized
by day 7 (Fig. 4A). As expected for the CDI hamster model, control
hamsters (6/6) developed mild to severe cecal dilation with or
without hemorrhage (Fig. 4B and C). The hamsters treated with
purified VNA2-Tcd also developed diarrhea between day 4 and
day 13 (10/11), but there was a trend for less severe cecal dilation
and hemorrhage (Fig. 4D and E) and a delay in the onset of symp-
toms (not shown). By Kaplan-Meier log rank test, survival was
significantly increased by VNA treatment (Fig. 4A; P  0.003).
Overall, the time frame suggests that the main beneficial effect was
delayed morbidity, as 90% of all hamsters eventually succumbed
by 200 h (8 days) post-spore administration. In the mouse model,
untreated mice succumbed to infection by day 2 or 3 post-spore
inoculation, and none of the treated mice became moribund.
Blood was collected from hamsters at the time of euthanasia,
and VNA2-Tcd serum levels were measured by ELISA, ranging
from 500 to 25,000 ng/ml (see Fig. S3A in the supplemental ma-
terial). Since blood was collected at the time of euthanasia only,
which occurred at various times throughout the experiment, and
hamsters received twice daily injections of VNA2-Tcd i.p., the
levels of VNA in serum varied widely, likely due to how soon after
the last treatment hamsters became moribund.
No significant differences were detected by light microscopic
examination of large intestinal tissue samples, including the ce-
cum, from control and treated groups (see Table S2 and Fig. S3B
in the supplemental material). Together, the clinical observations,
necropsy, and microscopic findings suggest that morbidity in the
hamster CDI model includes disease mechanisms that are inde-
pendent from those resulting in edema and neutrophilic inflam-
mation. Possibilities include electrolyte imbalances secondary to
diarrhea and dehydration, hypovolemic shock due to fluid loss,
and poor perfusion/reduced venous return to the heart secondary
to compression of the caudal vena cava from massively dilated
caeca.
Pig CDI challenge treated with the purified VNA2-Tcd pro-
tein. Two groups of 5-day-old gnotobiotic piglets (12 piglets)
were orally challenged with 106 UK6 spores. The treatment group
(3 piglets per treatment group and 6 untreated controls) was ini-
tially administered VNA2-Tcd (1 mg/kg) either 4 h prior to spore
challenge (via i.p. delivery route) or 18 h postchallenge (via i.m.
delivery route), followed by similar doses administered twice daily
for the duration of the experiment. Three out of six control pigs
were moribund (within 5 to 6 days post-spore inoculation) with
signs of weakness, lethargy, severe (copious/continuous yellow or
white mucoid or watery) diarrhea, and severe (red/bloody, exter-
nally visible, with thickening of the rectal wall) edematous rectal
prolapse (Table 2). All pigs in the control and VNA2-Tcd-treated
groups developed diarrhea within 48 h of inoculation with spores.
In contrast, the signs of CDI disease were much less severe in the
treated groups. Similar to mice and unlike the hamsters, none of
the treated pigs became moribund. In addition, none developed
rectal prolapse, and diarrhea was only mild to moderate in this
group (Table 2). Half of the control piglets had pleural effusion
and ascites (Fig. 5A and C). In contrast, pleural effusion and as-
cites were absent from VNA2-Tcd-treated piglets (Fig. 5B and D).
Control piglets also had moderate to severe mesocolonic edema
FIG 4 Protection against CDI in hamsters using VNA2-Tcd. (A) Survival
percentage with time for hamsters treated with VNA2-Tcd. The x axis shows
the hours after oral challenge with 1,000 UK6 spores. The y axis shows the
percentage of survival. The solid black line indicates survival in the VNA2-
Tcd-treated group, and the dashed black line indicates survival in the control
(PBS) group. The grouped survival data were analyzed by applying a Kaplan-
Meier log rank test using SigmaPlot (version 13.0; Systat Software, Inc.). The
log rank statistic for the survival curves is greater than would be expected by
chance, as the two curves show a statistically significant difference (P 0.003).
(B) Cecum (arrowhead) of a control hamster showing hemorrhage (arrow)
and dilation. (C) Cecum (arrowhead) of a control hamster showing dilation.
(D) Cecum (arrowhead) of a VNA2-Tcd-treated hamster showing dilation.
(E) Cecum of treated hamster showing no dilation.
TABLE 2 Pig clinical signs of disease
Treatment (no. of animals) Gastrointestinal disease (%)a Systemic disease (%)b Fatal disease (%)c
Uninfected control (3) Mild-moderate diarrhea (100), rectal prolapse (0) 0 0
UK6 spores VNA2-Tcd (6) Mild-moderate diarrhea (100), rectal prolapse (0) 0 0
UK6 spores VNA2-Tcd-Adeno (9) Mild-severe diarrhea (100), rectal prolapse (0) 0 0
UK6 spores buffer (6) Moderate-severe diarrhea (100), rectal prolapse (83) 50 50
UK6 spores control-Adeno (6) Moderate-severe diarrhea (100), rectal prolapse (50) 33 50
a Severity of gastrointestinal disease was determined by clinical signs of edema, hemorrhage, rectal prolapse, diarrhea, and gross and histopathologic lesions, ranging from mild to
severe.
b Systemic signs include pleural effusion and ascites.
c Fatal disease indicates that piglets were euthanized due to the severity of the disease.
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and dilation (Fig. 5C, E, and F) as well as hyperemia, mucosal
ulceration, and hemorrhages (not shown). In contrast, treated
piglets had mild to moderate mesocolonic edema with mild dila-
tion (Fig. 5G through I) and moderate hyperemia (not shown).
Microscopic examination of the large intestine identified sub-
mucosal edema as a cause of colonic mural thickening and muco-
sal neutrophilic infiltration as typical of CDI in piglets. As ex-
pected based on the clinical observations and gross findings, the
main difference observed by light microscopy reflected lesion se-
verity; more severe lesions were observed in the control versus
those in the VNA-treated piglets. There was a trend for more se-
vere submucosal edema in control piglets than in the VNA-treated
piglets (not shown). Similarly, there were more neutrophils in the
large intestines of the control piglets than in the VNA-treated
piglets (Fig. 6A and B), which reached statistical significance for
the distal colon (P  0.001) but not for the spiral colon (P 
0.0527). Some control pigs had epithelial ulceration associated
with neutrophilic colitis (Fig. 6C), while VNA-treated pigs did not
develop ulceration associated with neutrophilic colitis (Fig. 6D).
Blood collected from pigs one time during the course of the
experiment and at euthanasia determined that VNA2-Tcd serum
levels ranged from 2.7 to 4.7 g/ml (see Fig. S2C in the supple-
mental material). However, as observed in mice, serum neutral-
ization abilities tested by cell cytotoxicity assay were similar for all
treated pigs with a 1:2 dilution of serum providing about 50%
reduction in cytotoxicity/cell rounding (Fig. S2D).
Pig CDI challenge following gene therapy using adenovirus
expressing VNA2-Tcd. To further corroborate the efficacy of
VNA2-Tcd in treating pigs for CDI, we employed a gene therapy
approach in which an adenovirus vector (Ad/VNA2-Tcd) was ad-
ministered that could promote the in vivo expression and secre-
tion of VNA2-Tcd into the serum of treated pigs. A total of 15
gnotobiotic pigs were used to assess the effectiveness of Ad/VNA2-
Tcd. Six control pigs were administered 1.0 1011 vp of adenovi-
FIG5 Necropsy images from piglets infected with C. difficile. (A) Control piglet with pleural effusion (arrow), lung displaying diffuse hyperemia and congestion.
(B) VNA2-Tcd-treated piglet with a normally aerated lung and no visible pleural effusion. (C) Control piglet with ascites (arrow), moderate dilation, mesocolonic
edema, and hyperemia in the spiral colon. (D) VNA2-Tcd-treated piglet with moderate dilation and mild mesocolonic edema in the spiral colon. (E to I)
Necropsy images of spiral colons from control and VNA2-Tcd-treated pigs inoculated with C. difficile spores. (E) Moderate mesocolonic edema, (arrow)
hyperemia, focal mucosal ulceration, hemorrhages, and dilation in a control piglet. (F) Severe mesocolonic edema (arrow) in a control piglet. (G) Mild
mesocolonic edema (arrow), dilation, and moderate hyperemia in a VNA2-Tcd-treated piglet. (H) Dilation and hyperemia in a VNA2-Tcd-treated piglet. (I)
Dilation and hyperemia in an Ad/VNA2-Tcd-treated piglet. (J and K) Comparison of descending colons of control and VNA2-Tcd-treated piglets. Similar
sections of the distal descending colon, approximately 6 cm in length, were collected from control and treated piglets at the time of necropsy. (J) Sections from
control piglets demonstrating severe dilation, mesocolonic edema, multifocal hemorrhages, and thickening of the intestinal wall. (K) Sections from VNA2-Tcd-
treated (purified or adenovirus expressing) piglets that show minimal or no dilation, no intestinal wall thickening, or hemorrhages.
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rus (i.v.) expressing an unrelated VNA, and 9 pigs were adminis-
tered 1.0  1011 vp of Ad/VNA2-Tcd (i.v.). Each pig was treated
twice with Ad/VNA2-Tcd, 1 day prior to oral inoculation with 106
UK6 C. difficile spores and again 3 days after spore exposure. All
six pigs in the control groups developed diarrhea within 48 h of
inoculation with spores. Three of the six control pigs became mor-
ibund, all had moderate to severe diarrhea, and two had systemic
signs of disease, including pleural effusion and ascites (Table 2). In
contrast, none of the nine Ad/VNA2-Tcd-treated pigs became
moribund, and diarrhea was predominantly mild to moderate
with no other signs of disease (Table 2 and Fig. 5I and K). Micro-
scopic examination again supported the trend that VNA treat-
ment reduced lesion severity. More specifically, it was noted that
treated pigs with high serum VNA levels had predominantly mild
to moderate edema with two pigs (numbers 1 and 14), while pigs
with low VNA levels showed marked edema (Table 3). Further-
more, Ad/VNA-treated pigs with the highest levels of serum VNA
(numbers 6 and 13) had minimal or no edema (Table 3). Two of
six control pigs (numbers 7 and 15) showed minimal to marked
levels of edema (Table 3).
FIG 6 Evaluation of neutrophilic foci and histopathologic lesions in the colon and large intestine. (A and B) Quantitative evaluation of neutrophilic foci in distal
colon (A) and spiral colon (B) of untreated control and VNA-treated piglets. (C) Untreated piglets with mucosal ulceration, hemorrhage, and marked
neutrophilic infiltration and eruption of neutrophils and sloughed mucosa into the intestinal lumen. (D) Treated piglets with mild mucosal erosion and
neutrophilic infiltration.









colitis Epithelium Luminal contents
5 4 160 /  /  Intact None
9 1 300  /   Intact None
12 3 350     Intact None
13 4 1,000    / Intact None
6 0 1,600   /  Intact None
1 3 30 NAa    Intact Necrotic cell debris
()
2 3 100    / Intact None
14 10 150     Ulcerated Necrotic cell debris
()
7b 9 0  /   Intact None
15b 11 0     Intact None
a NA, not available.
b These were control pigs that were treated with an unrelated VNA.
c, none;/, mild to none;, mild;, moderate;, severe.
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To determine whether there was a significant correlation be-
tween the severity of symptoms and the serum level of VNA2-Tcd,
blood was collected from pigs one to three times during the course
of the experiment and at euthanasia. Serum ELISAs showed that
VNA2-Tcd serum levels ranged from 20 to 1,600 ng/ml at multiple
time points during the experiment (Fig. 7A). The association be-
tween VNA concentration in pig serum and disease severity was
analyzed using the Spearman rank correlation. This analysis dem-
onstrated a significant negative relationship in which increased
serum VNA concentration was clearly associated with lower CDI
severity score (r0.614; P 0.0443) (Fig. 7B).
DISCUSSION
A single tetraspecific VNA protein comprised of four unique VHH
binding agents, two each targeting C. difficile toxin A or toxin B at
distinct neutralizing epitopes, reduced the severity of CDI clinical
parameters and lesions in three different animal models: mice,
hamsters, and gnotobiotic pigs. We expressed and purified VNA2-
Tcd, tested the agent for in vitro toxin binding and neutralization
activity, and then used the VNA to treat mice that received sys-
temically delivered Tcd toxins. In the mouse model, a single dose
of VNA (containing an albumin-binding peptide that improves
VNA serum persistence in mice [60]) fully protected all groups
that received the VNA against any signs or symptoms of toxemia,
while all of the untreated mice died within 4 h of toxin adminis-
tration. The same purified VNA2-Tcd also significantly protected
mice, hamsters, and gnotobiotic piglets against systemic signs of
disease in CDI challenge models. In these models, the toxins, likely
leaking from intestinal lesions, enter the peritoneal space and
bloodstream, inducing toxemia and systemic complications, such
as ascites and pleural effusion (69, 70).
Since the VNA was administered systemically, we did not nec-
essarily expect to see a significant protective effect on the integrity
of the mucosa or the gastrointestinal (GI) tract; however, previous
results indicated that there was a possibility that the VNA2-Tcd
would be partially protective against GI pathology (56, 71). In
mice and pigs, there was a significant protective effect against di-
arrhea, edema, and hemorrhage in addition to protection against
systemic disease. VNA2-Tcd showed protection when adminis-
tered i.p. against diarrhea in the mouse model (80% after the first
dose and 100% after the second dose) and against edema and
severe diarrhea in the piglet model. This suggests an ability of the
agent to be effectively absorbed either through intestinal lesions
(56, 71), loosening of epithelial cell tight junctions, or through
normal portal absorption to some degree, thereby mitigating the
effects of the toxin on microvillus degradation and neutrophil
infiltration in the lamina propria and edema in the spiral and
distal colon.
The difference seen in protection against GI disease between
the mouse and piglet models of CDI may be attributed, at least in
part, to the difference in the serum levels of VNA achieved by the
different treatments. The mice received three doses of 1.25 to 2.5
mg/kg/day, while the hamsters and piglets received a dose of 1 to 2
mg/kg/day. Perhaps more important, the VNA contains an albu-
min-binding peptide that was selected for mouse albumin affinity
(72). This peptide substantially increases the half-life of the VNA
in mouse serum but has little or no apparent affinity for albumins
from other species (60), such as pigs, and therefore, is unlikely to
extend serum half-life. Increasing the dose of VNA administered
to hamsters and piglets and/or employing a VNA with an albu-
min-binding peptide that binds hamster and pig albumin would
likely improve its efficacy in these models to become closer to the
high levels achieved in the mouse model.
Generally, the hamster model of CDI is extremely sensitive and
requires as few as 100 spores to induce diarrhea (73). However,
hamsters were reported to be relatively resistant to the UK6 strain
of C. difficile (68). We did induce CDI disease in 100% of Syrian
hamsters using 1,000 UK6 spores and found that any sign of diar-
rhea in hamsters was always fatal in our model. Hamsters some-
times died prior to external signs of diarrhea (wet tail) but with
internal signs (lack of formed feces in the GI tract). Diarrhea in
mice and pigs ranged in severity, and only severe diarrhea and
systemic disease proved fatal in these animals. Since our treatment
is designed to protect against the systemic effects of CDI, with only
limited access to the GI tract, it is not surprising that this treatment
was less effective in our hamster model where hamsters did not
develop systemic disease and instead became moribund very soon
after displaying symptoms of GI disease. Together, the clinical
FIG 7 Ad/VNA2-Tcd detection in serum and disease correlation. (A) VNA2-Tcd levels detected in pig serum by ELISA using 0.5 g/ml of TcdA or TcdB and
serum diluted 1:10. Samples 7 and 15 correspond to control animals (unrelated Ad/VNA-treated piglets), and the remaining samples correspond to Ad/VNA2-
Tcd-treated piglets. (B) CDI severity versus serum VNA concentration in pigs treated with Ad/VNA2-Tcd, assessed with Spearman’s rank correlation (rS 
0.614; P 0.04433). The dashed lines show the 95% confidence interval.
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observations, necropsy, and microscopic findings suggest that
morbidity in the hamster CDI model includes disease mecha-
nisms that are independent from those resulting in edema and
neutrophilic inflammation. Possibilities include electrolyte im-
balances secondary to diarrhea and dehydration, hypovolemic
shock due to fluid loss, and poor perfusion/reduced venous return
to the heart secondary to compression of the caudal vena cava
from massively dilated caeca.
Finding a method for the oral administration of the bioactive
VNA may permit the more effective protection against diarrhea
and edema seen in the hamster and piglet CDI treatment groups.
Although VHHs are generally more stable to pH and temperature
extremes than conventional antibodies (50), it seems likely that
heteromultimeric VNAs will be susceptible to gastric enzyme deg-
radation. To overcome this problem, VNAs may be lyophilized
and delivered in drug capsules, using a nanoparticle delivery sys-
tem, or by some form of gene therapy that promotes expression of
VNA2-Tcd into the GI lumen (e.g., recombinant Lactococcus lac-
tis) (74). Alternatively, an adenovirus that promotes secretion of
VNA2-Tcd and that is engineered to selectively transduce intesti-
nal epithelial cells (75, 76) may reduce intestinal edema and in-
flammation and the severity of diarrhea.
VNA2-Tcd is directed against the two secreted toxins, not
against the bacteria, and does not involve the use of antibiotic
therapy. Therefore, treatment with VNA2-Tcd is unlikely to pro-
mote the occurrence of relapse associated with antibiotic treat-
ments against CDI, which is the major cause of fatal disease in
humans (1). Previous results using therapeutic antibodies against
CDI suggest that this is possible (35).
Using a single tetraspecific agent to express a polyprotein with
multiple linked VHHs against two different Tcd toxins, and the
feasibility of using microbial hosts for production, reduces man-
ufacturing costs and reduces the complexity of clinical trials. The
addition of an albumin-binding peptide that effectively binds hu-
man albumin would increase the serum persistence of the VNA,
thereby increasing steady-state serum levels and reducing the fre-
quency of doses required to effectively treat CDI pathology. The
fact that VNAs can be effectively delivered by gene therapy (63–
65) opens the possibility of developing single-dose therapies that
provide prolonged efficacy and protect patients from relapses.
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